1. Introduction

Neurological complications of hematological diseases occupy a paradoxical position within contemporary medicine. They are both well-described and persistently under-recognized, biologically complex yet systemically determined, and often treated as secondary phenomena despite their profound contribution to morbidity and mortality. This tension becomes particularly pronounced in low- and middle-income countries (LMICs), where structural limitations intersect with high disease burden and reshape the clinical expression of disease.

The mechanisms underlying neurological involvement are diverse, encompassing cerebrovascular complications, direct central nervous system (CNS) infiltration, immune-mediated processes, metabolic disturbances, infections, and treatment-related neurotoxicity.1–3 These mechanisms frequently overlap, particularly in patients exposed to intensive therapies such as hematopoietic stem cell transplantation (HSCT), where endothelial injury, immune dysregulation, and pharmacological toxicity converge.2–4

While such biological pathways are broadly consistent across settings, their clinical consequences are not. In LMICs, limited access to timely diagnosis, neuroimaging, and multidisciplinary care shifts neurological complications toward later, more severe, and often irreversible stages of disease. In this context, neurological involvement emerges not merely as a complication but as a reflection of systemic delay and constraint.

2. Biological Convergence and Contextual Amplification

The nervous system functions as a critical interface through which systemic hematological disturbances become clinically manifest. Coagulopathy, thrombocytopenia, hyperviscosity, and immune dysregulation create a milieu in which both ischemic and hemorrhagic events are common.3–5 Simultaneously, malignant infiltration of the CNS and paraneoplastic immune responses further expand the spectrum of neurological disease.1

In LMICs, however, these processes are amplified by contextual factors. Infectious complications remain a dominant driver of neurological morbidity, particularly in immunocompromised populations. Opportunistic infections involving the CNS—ranging from viral encephalitides to fungal and parasitic diseases—are more prevalent and more severe in settings where infectious burden remains high and access to early treatment is inconsistent.6,7 The coexistence of HIV and hematological disorders in many LMICs creates a particularly complex clinical landscape, in which immune dysfunction, infection, and malignancy interact in mutually reinforcing ways.

Non-infectious complications are similarly shaped by systemic constraints. Intracranial hemorrhage, often associated with thrombocytopenia or coagulopathy, remains a major cause of mortality. Yet its clinical impact is magnified by delays in recognition and limited access to neurocritical care.5,8 Ischemic stroke, driven by malignancy-associated hypercoagulability, presents additional challenges in environments where anticoagulation monitoring and imaging are not readily available.

Thus, while the biological mechanisms of neurological injury are shared globally, their clinical expression is profoundly influenced by infrastructure. In LMICs, these complications are not only more frequent but also more advanced at presentation and less amenable to intervention.

3. Delay, Diagnostic Limitations, and the Reshaping of Clinical Trajectories

A central determinant of neurological outcome in LMICs is the delay between symptom onset and definitive diagnosis. Patients frequently navigate fragmented healthcare systems, encountering multiple providers before reaching specialized care.9 During this interval, hematological diseases progress unchecked, increasing the likelihood of CNS involvement.

Neurological symptoms often emerge as late-stage manifestations rather than early warning signs. Headache, altered consciousness, seizures, or focal deficits may represent the culmination of prolonged pathological processes rather than their onset. By the time such symptoms are recognized, structural damage may already be established, limiting the effectiveness of therapeutic interventions.

Diagnostic limitations further compound this problem. Access to magnetic resonance imaging, advanced laboratory testing, and specialist evaluation remains uneven across LMICs.10 In their absence, clinicians must rely heavily on clinical judgment, often in the face of overlapping and nonspecific presentations. This increases the risk of both underdiagnosis and misdiagnosis, particularly in distinguishing between infectious, vascular, and malignant causes of neurological dysfunction.

The result is a transformation of disease trajectory, in which conditions that might be manageable in earlier stages become life-threatening or disabling.

4. Therapeutic Advances and Emerging Neurotoxicity

The therapeutic landscape of hematology has undergone rapid transformation, with the introduction of targeted therapies, immunotherapies, and cellular treatments. These innovations have significantly improved survival in many hematological malignancies but have also introduced a new spectrum of neurological complications.1,11

Immune-mediated neurotoxicity, including encephalopathy and seizure syndromes, has become increasingly recognized, particularly in association with novel immunotherapies.11,12 In high-income settings, structured monitoring protocols and multidisciplinary teams have evolved to address these complications. In LMICs, however, access to such therapies is limited, and when available, the infrastructure required for safe administration and monitoring is often insufficient.

This creates a paradox in which therapeutic innovation coexists with systemic vulnerability. Patients may either lack access to life-saving treatments or receive them in contexts where their complications cannot be adequately managed. In both scenarios, neurological outcomes are adversely affected.

5. Neurological Complications as System-Level Indicators

Neurological complications provide a unique lens through which the performance of health systems can be assessed. Their occurrence reflects not only the biological severity of disease but also the effectiveness of diagnosis, treatment, and supportive care.

High rates of CNS infections point to gaps in infection control and immunosuppression management. Frequent hemorrhagic complications suggest limitations in transfusion services and coagulation monitoring. Delayed recognition of neurotoxicity highlights the absence of integrated care models linking hematology and neurology. In each case, neurological manifestations reveal underlying structural constraints that extend beyond the individual patient.10,13

This perspective reframes neurological complications as integrative indicators of system function, emphasizing the need for interventions that address both clinical and infrastructural determinants of disease.

6. Toward Integrated and Context-Sensitive Care

Addressing neurological complications in LMICs requires a shift toward integrated, context-sensitive models of care. Early recognition of neurological symptoms must be prioritized, supported by clear referral pathways and improved clinical training. Even in resource-limited settings, strengthening collaboration between hematologists, neurologists, and critical care providers can enhance diagnostic accuracy and treatment outcomes.

At the same time, diagnostic and therapeutic strategies must be adapted to local realities. While advanced technologies remain important, significant gains can be achieved through the optimization of existing resources, including basic imaging, laboratory testing, and supportive care.14 Ensuring access to transfusion services, antimicrobial therapies, and essential neurocritical care may have a greater impact than the isolated introduction of high-cost interventions.

Finally, expanding research capacity in LMICs is essential for generating context-specific evidence. Current knowledge remains disproportionately derived from high-income settings, limiting its applicability to diverse populations and healthcare environments.13,15

7. Conclusion

Neurological complications of hematological diseases in LMICs represent a convergence of biological vulnerability and structural inequality. While the underlying mechanisms of disease are universal, their clinical expression is profoundly shaped by context, transforming potentially manageable conditions into major sources of morbidity and mortality.

Reframing these complications as indicators of health system performance provides a pathway toward more effective and equitable care. By integrating neurological and hematological expertise, improving early recognition, and aligning therapeutic advances with local capacity, it is possible to mitigate the burden of neurological disease in these settings.

Ultimately, the challenge is not only to treat neurological complications, but to address the systems in which they arise.

Conflict of interest statement

The author declares that there is no conflict of interest.